Stock GILD GILEAD SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Gilead Sciences, Inc. Buenos Aires S.E.

Equities

GILD

ARBCOM4601C4

End-of-day quote Buenos Aires S.E.
Other stock markets
 23:00:00 18/06/2024 BST 		5-day change 1st Jan Change
20,519 ARS +3.15% Intraday chart for Gilead Sciences, Inc. +1.25% +3.79%
06-20 Equity Markets Close Mixed as Investors Weigh Economic Data MT
06-20 Equity Markets Close Mixed After Macro Data MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • This company will be of major interest to investors in search of a high dividend stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 200.25 times its estimated earnings per share for the ongoing year.
  • With an enterprise value anticipated at 3.75 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The company appears highly valued given the size of its balance sheet.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
GILEAD SCIENCES, INC. Stock Gilead Sciences, Inc.
+3.79% 85.33B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+51.99% 798B
C+
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.72% 356B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.94% 328B
B-
ABBVIE INC. Stock AbbVie Inc.
+11.07% 304B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.96% 244B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.25% 227B
A+
NOVARTIS AG Stock Novartis AG
+11.15% 216B
B-
AMGEN INC. Stock Amgen Inc.
+7.59% 166B
C+
PFIZER, INC. Stock Pfizer, Inc.
-3.65% 157B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. GILD Stock
  5. Ratings Gilead Sciences, Inc.